COVID pre-exposure prophylaxis for pregnant women is a critical issue as pregnant women are at higher risk for developing severe complications of COVID infections including preterm delivery, fetal demise, respiratory failure and maternal death. As pregnant women initially may not be eligible to receive COVID-19 vaccines due to the unknown effects on mother and fetus, these women urgently need an option for protection from COVID when vaccine candidates are not available to them.
A peer-reviewed report, co-authored by Melissa C. Fesler and Raphael B. Stricker, has been published in the International Journal of General Medicine which evaluates pre-exposure prophylaxis (PrEP) with medications approved for use in pregnant women to prevent gestational problems and severe illness in this high-risk population.
This report evaluates pre-exposure prophylaxis medications with findings that hydroxychloroquine (HCQ) may provide the safest most effective means to reduce effects of or prevent SARS-CoV-2 infection in pregnancy.
Read 24/7 press release here.
Read published study: Fesler MC, Stricker RB. Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women. Int J Gen Med. 2021;14:279-284 https://doi.org/10.2147/IJGM.S295627
Read other COVID related LDA posts here.